Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fuzuloparib + abiraterone acetate + prednisone + androgen deprivation therapy
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Peptides, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
This combination therapy regimen is being evaluated in the Phase 2 FAST-PC trial (NCT05223582) led by Fudan University Shanghai Cancer Center for the neoadjuvant treatment of high-risk localized prostate cancer. The regimen consists of fuzuloparib (a PARP inhibitor), abiraterone acetate (a CYP17 inhibitor), prednisone, and androgen deprivation therapy (ADT) using LHRH agonists. Fuzuloparib, developed by Jiangsu Hengrui Pharmaceuticals, inhibits poly(adenosine diphosphate-ribose) polymerase (PARP) enzymes to disrupt DNA repair mechanisms. Abiraterone acetate blocks androgen biosynthesis by inhibiting the CYP17A1 enzyme, and prednisone is co-administered to manage mineralocorticoid excess. The combination aims to provide a synergistic therapeutic effect by simultaneously targeting the androgen receptor signaling pathway and DNA damage repair pathways in prostate cancer cells prior to radical prostatectomy.
- Other names
- androgen deprivation therapy-Fudan University-prostate cancerFAST trial regimenfluzoparib + abiraterone + prednisone + ADT
02
Targets
MR (Mineralocorticoid receptor)3β-HSD (3β-Hydroxysteroid Dehydrogenase/Δ5-4 isomerase type 1)HSD3B2 (3-beta-hydroxysteroid dehydrogenase type 2)GR (Glucocorticoid receptor)CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GnRHR (Gonadotropin-releasing hormone receptor)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on fuzuloparib + abiraterone acetate + prednisone + androgen deprivation therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fuzuloparib + abiraterone acetate + prednisone + androgen deprivation therapy.